CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.

about

CDK4/6 blockade in breast cancer: current experience and future perspectives.MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer.CDK4/6 inhibition in breast cancer: current practice and future directions

P2860

Q47658848-9320C01C-7031-4165-995F-2C133A9EEF9A Q53685801-F18F0072-16E6-4700-AED7-AD286B5B9B44 Q57109486-117AEF76-0708-4CBA-A727-F5E7352F8561

P2860

CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.

Item

http://www.wikidata.org/entity/Q39289608

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.

@en

CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.

@nl

type

Item

label

CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.

@en

CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.

@nl

prefLabel

CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.

@en

CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.

@nl

P1476

CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.

@en

P2093

Ana C Garrido-Castro

http://www.w3.org/2001/XMLSchema#string

Shom Goel

http://www.w3.org/2001/XMLSchema#string

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells

Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function

Comprehensive molecular portraits of human breast tumours

Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1)

Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers

Targeting CDK4 and CDK6: From Discovery to Therapy

P2888

s12609-017-0232-0

P304

26-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12609-017-0232-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28479958

http://www.w3.org/2001/XMLSchema#string

P932

5414585

http://www.w3.org/2001/XMLSchema#string

CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.

about

P2860

P2860

CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P932